On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
Lisdexamfetamine dimesylate ( LDX ) is a long-acting , prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder ( ADHD ) . This r and omized placebo-controlled trial of an optimized daily dose of LDX ( 30 , 50 or 70 mg ) was conducted in children and adolescents ( aged 6–17 years ) with ADHD . To evaluate the efficacy of LDX throughout the day , symptoms and behaviors of ADHD were evaluated using an abbreviated version of the Conners ’ Parent Rating Scale-Revised ( CPRS-R ) at 1000 , 1400 and 1800 hours following early morning dosing ( 0700 hours ) . Osmotic-release oral system methylpheni date ( OROS-MPH ) was included as a reference treatment , but the study was not design ed to support a statistical comparison between LDX and OROS-MPH . The full analysis set comprised 317 patients ( LDX , n = 104 ; placebo , n = 106 ; OROS-MPH , n = 107 ) . At baseline , CPRS-R total scores were similar across treatment groups . At endpoint , differences ( active treatment − placebo ) in least squares ( LS ) mean change from baseline CPRS-R total scores were statistically significant ( P < 0.001 ) throughout the day for LDX ( effect sizes : 1000 hours , 1.42 ; 1400 hours , 1.41 ; 1800 hours , 1.30 ) and OROS-MPH ( effect sizes : 1000 hours , 1.04 ; 1400 hours , 0.98 ; 1800 hours , 0.92 ) . Differences in LS mean change from baseline to endpoint were statistically significant ( P < 0.001 ) for both active treatments in all four subscales of the CPRS-R ( ADHD index , oppositional , hyperactivity and cognitive ) . In conclusion , improvements relative to placebo in ADHD-related symptoms and behaviors in children and adolescents receiving a single morning dose of LDX or OROS-MPH were maintained throughout the day and were ongoing at the last measurement in the evening ( 1800 hours )
On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .